YaSheng Group (HERB)

[aandt]

Yeah confusing as usual.

But Promab does look interesting.

Here is the team on the Chinese website. 2nd picture is John Wu, mentioned in the PR. http://www.promab.cn/team.php?id=159

The Chinese name is YuanTai

http://career.csu.edu.cn/company/view/id/505627

Hunan Yuantai Biotech Co., Ltd. was established in 2001, and will soon become a multinational biopharmaceutical enterprise headquartered in Shanghai. It has three R&D and production bases in Shanghai, San Francisco Bay Area (ProMab Biotech) and Changsha. As a means of large-scale production of monoclonal antibodies and recombinant proteins, clinical diagnostic technology and targeted new drug research and development enterprises. Under the leadership of a number of European and American scholars and a team with rich business management experience, through unremitting efforts, we have successfully established three antibody technology platforms of mouse origin, rabbit origin and human origin in the world, and focused on the development of immunotherapy. and innovative technologies such as antibody drugs. The company has now passed the ISO9001 quality system certification, and has obtained a number of national invention patents.

Since 2018, the company has deployed in the field of immunotherapy and built a laboratory that meets GMP standards. At the beginning of 2020, the company raised a new investment of 80 million yuan, and built a production and research and development base of more than 4,000 square meters in Changsha High-tech Zone that meets GMP standards. As a technology and patent-driven enterprise, the company will give full play to its overseas background and channel advantages, and comprehensively deploy the global market. Based on scientific research and industrial antibody production, the company will take the development of antibody drugs as development opportunities, and the clinical application of immune cell drugs as a take-off. The goal is to create a unique way of operation and research and development. At the same time, through close cooperation with scientists, biotechnology companies and pharmaceutical companies from all over the world, the company has established its position in the global bio-industry by establishing high-quality, reliable, efficient and high-quality services, and has developed a unique style on the international stage.

Looks like Promab was acquired by NanHua for 51.3M RMB (7.5M USD) in 2017.

http://ifinance.ifeng.com/15838318/news.shtml?&back

But then it was valued at 97.2M RMB (14.2M USD) in 2019 and sold?

https://m.bjnews.com.cn/detail/156741535314862.html

https://www.sohu.com/a/317538379_114988

And see the above, raised new investment of 80M RMB in 2020 to build base in China. Looks like the US branch is one of three.